FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014784691> ?p ?o ?g. }

• W2014784691 endingPage "80" @default.
• W2014784691 startingPage "65" @default.
• W2014784691 abstract "Modified nanoprecipitation method was used for improved incorporation of hydrophilic drug (irinotecan hydrochloride) into the PLGA/PEO-PPO-PEO blended and blended/adsorbed nanoparticles. One factor at a time (OFAT) variation experiments were conducted in order to determine key formulation factors (concentration and volume of drug solution, evaporation rate and PLGA/PEO-PPO-PEO ratio) influencing nanoparticle properties (particle size and size distribution, encapsulation efficiency, drug content, zeta potential, drug dissolution rate, as well as protein binding capacity). The insight into in vivo behavior of prepared nanoparticles and their potential for effective anticancer treatment was gained by performing biodistribution and cell culture studies as part of OFAT experiments. The mean particle size, mainly dependent upon PLGA/PEO-PPO-PEO ratio, was in the range of 112-125 nm, with narrow unimodal distribution (PDI∼0.1). Encapsulation efficiency (32-63%) was impacted by evaporation rate and PLGA/PEO-PPO-PEO ratio. Drug content (0.2-1.51%) and controlled release properties were related to the influence of all tested formulation factors. Structural information for the studied nanoparticles was obtained using DSC and FT-IR spectroscopy. Zeta potential values indicated that presence of PEO-PPO-PEO in the formulations shielded the high surface negative charge of PLGA. PEO-PPO-PEO surface coverage of PLGA/PEO-PPO-PEO blended as well as blended/adsorbed nanoparticles depended upon amount of used PEO-PPO-PEO during preparation procedure and was related to the protein resistant characteristics of nanoparticles. Results from in vivo studies evidenced prolonged blood circulation time of the prepared nanoparticles, while cell culture studies indicated higher in vitro bioefficacy compared to free drug. Performed experiments defined possible design space and justified further optimization of formulation using experimental design studies." @default.
• W2014784691 created "2016-06-24" @default.
• W2014784691 creator A5001760466 @default.
• W2014784691 creator A5002276219 @default.
• W2014784691 creator A5006635779 @default.
• W2014784691 creator A5020443497 @default.
• W2014784691 creator A5033216954 @default.
• W2014784691 creator A5045878207 @default.
• W2014784691 creator A5046600876 @default.
• W2014784691 creator A5061510247 @default.
• W2014784691 creator A5081101266 @default.
• W2014784691 date "2013-04-01" @default.
• W2014784691 modified "2023-09-27" @default.
• W2014784691 title "Definition of formulation design space, in vitro bioactivity and in vivo biodistribution for hydrophilic drug loaded PLGA/PEO–PPO–PEO nanoparticles using OFAT experiments" @default.
• W2014784691 cites W1518912495 @default.
• W2014784691 cites W1535005981 @default.
• W2014784691 cites W1964508699 @default.
• W2014784691 cites W1968900010 @default.
• W2014784691 cites W1973195136 @default.
• W2014784691 cites W1976041621 @default.
• W2014784691 cites W1976947632 @default.
• W2014784691 cites W1980559497 @default.
• W2014784691 cites W1986249683 @default.
• W2014784691 cites W1986901350 @default.
• W2014784691 cites W1988652094 @default.
• W2014784691 cites W1988782305 @default.
• W2014784691 cites W1988866388 @default.
• W2014784691 cites W1989359894 @default.
• W2014784691 cites W1990648838 @default.
• W2014784691 cites W1991300039 @default.
• W2014784691 cites W1995634417 @default.
• W2014784691 cites W1996998905 @default.
• W2014784691 cites W1997118112 @default.
• W2014784691 cites W1998394552 @default.
• W2014784691 cites W2002695992 @default.
• W2014784691 cites W2003742048 @default.
• W2014784691 cites W2007445878 @default.
• W2014784691 cites W2009974403 @default.
• W2014784691 cites W2013971224 @default.
• W2014784691 cites W2017993118 @default.
• W2014784691 cites W2019911171 @default.
• W2014784691 cites W2020829673 @default.
• W2014784691 cites W2021876818 @default.
• W2014784691 cites W2023806031 @default.
• W2014784691 cites W2029677759 @default.
• W2014784691 cites W2032433624 @default.
• W2014784691 cites W2034214145 @default.
• W2014784691 cites W2038281022 @default.
• W2014784691 cites W2045399835 @default.
• W2014784691 cites W2051305606 @default.
• W2014784691 cites W2059862524 @default.
• W2014784691 cites W2064166641 @default.
• W2014784691 cites W2066354221 @default.
• W2014784691 cites W2066467350 @default.
• W2014784691 cites W2066626756 @default.
• W2014784691 cites W2069920467 @default.
• W2014784691 cites W2071636590 @default.
• W2014784691 cites W2072954285 @default.
• W2014784691 cites W2083980374 @default.
• W2014784691 cites W2085240545 @default.
• W2014784691 cites W2094135334 @default.
• W2014784691 cites W2101312385 @default.
• W2014784691 cites W2115439624 @default.
• W2014784691 cites W2126107019 @default.
• W2014784691 cites W2133338994 @default.
• W2014784691 cites W2143208806 @default.
• W2014784691 cites W2148192899 @default.
• W2014784691 cites W2154043786 @default.
• W2014784691 cites W2163121767 @default.
• W2014784691 cites W2164533531 @default.
• W2014784691 cites W2167924652 @default.
• W2014784691 cites W2171792381 @default.
• W2014784691 cites W2612545602 @default.
• W2014784691 cites W4297069849 @default.
• W2014784691 cites W43532378 @default.
• W2014784691 doi "https://doi.org/10.1016/j.ejps.2013.02.004" @default.
• W2014784691 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23439240" @default.
• W2014784691 hasPublicationYear "2013" @default.
• W2014784691 type Work @default.
• W2014784691 sameAs 2014784691 @default.
• W2014784691 citedByCount "11" @default.
• W2014784691 countsByYear W20147846912014 @default.
• W2014784691 countsByYear W20147846912016 @default.
• W2014784691 countsByYear W20147846912017 @default.
• W2014784691 countsByYear W20147846912018 @default.
• W2014784691 countsByYear W20147846912019 @default.
• W2014784691 countsByYear W20147846912020 @default.
• W2014784691 countsByYear W20147846912023 @default.
• W2014784691 crossrefType "journal-article" @default.
• W2014784691 hasAuthorship W2014784691A5001760466 @default.
• W2014784691 hasAuthorship W2014784691A5002276219 @default.
• W2014784691 hasAuthorship W2014784691A5006635779 @default.
• W2014784691 hasAuthorship W2014784691A5020443497 @default.
• W2014784691 hasAuthorship W2014784691A5033216954 @default.
• W2014784691 hasAuthorship W2014784691A5045878207 @default.
• W2014784691 hasAuthorship W2014784691A5046600876 @default.
• W2014784691 hasAuthorship W2014784691A5061510247 @default.
• W2014784691 hasAuthorship W2014784691A5081101266 @default.

• next